Significantly lower risk is seen for recovery. 2 studies (both from the same team) show significant benefit.
Meta analysis using the most serious outcome reported shows 74% [-20‑94%] lower risk, without reaching statistical significance. Results are worse for Randomized Controlled Trials.
Currently there is limited data, with only 605 patients in trials to date. Studies to date are from only 3 different groups.
Concerns have been raised over potential harm with the use of NSAIDs for COVID-19 due to the suppression of beneficial immune and inflammatory responses during early infection, and delaying further care. There are currently no early treatment studies for indomethacin. Early treatment results for NSAID ibuprofen suggest higher risk. Indomethacin may be beneficial for cough1, which may not respond to other treatments.
No treatment is 100% effective. Protocols combine safe and effective options with individual risk/benefit analysis and monitoring. Indomethacin currently has no early treatment studies. All data and sources to reproduce this analysis are in the appendix.
Covid Analysis et al., Dec 2024, preprint, 1 author.
